 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Progen Industries Limited
 |
Progen Industries Limited |
 |
 |
 |
PROFILE |
 |
Progen has high hopes for its progeny. A biotech from the land down under, Progen makes molecular biology reagents, kits, and bulk proteins; it also offers contract research services to other biotechs and pharmaceutical companies. Its flagship drug, PI-88, is being tested for cancer-fighting applications. The company is also developing drugs to treat thrombosis, inflammatory disease, hypertriglyceridaemia (a condition linked to higher risk of heart disease and arteriosclerosis), and restenosis (in which arteries that have been cleared through angioplasty re-clog). Progen is the Australian distributor of Clontech Laboratories' gene research kits.
COMPETITION |
 |
Endogen, Inc. (dossier)
PAREXEL International Corporation (PRXL)
Quintiles Transnational Corp. (QTRN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 1.50
1-Yr. Sales Growth: 66.7%
Employees: 42
Revenue per employee: $35,714.29
KEY PEOPLE |
 |
Lewis Lee
CEO
Charles Furness
CFO
CONTACT INFO |
 |
2806 Ipswich Rd.
Darra Queensland 4076, Australia
Phone: 61-732-9100
Fax: 61-733-9318
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |